NASDAQ:SPRO - Spero Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.11 -0.13 (-1.58 %) (As of 01/16/2019 04:46 AM ET)Previous Close$8.24Today's Range$8.04 - $8.3452-Week Range$5.52 - $19.00Volume29,800 shsAverage Volume56,170 shsMarket Capitalization$141.26 millionP/E Ratio-0.46Dividend YieldN/ABeta1.18 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive SPRO News and Ratings via Email Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO Previous Symbol CUSIPN/A Webwww.sperotherapeutics.com Phone857-242-1600Debt Debt-to-Equity RatioN/A Current Ratio13.02 Quick Ratio13.02Price-To-Earnings Trailing P/E Ratio-0.46 Forward P/E Ratio-2.92 P/E GrowthN/A Sales & Book Value Annual Sales$1.98 million Price / Sales70.49 Cash FlowN/A Price / Cash FlowN/A Book Value$5.91 per share Price / Book1.37Profitability EPS (Most Recent Fiscal Year)($17.82) Net Income$-38,740,000.00 Net Margins-1,402.91% Return on Equity-52.22% Return on Assets-47.84%Miscellaneous Employees35 Outstanding Shares17,210,000Market Cap$141.26 million OptionableOptionable Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." How were Spero Therapeutics' earnings last quarter? Spero Therapeutics Inc (NASDAQ:SPRO) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.04. The business earned $0.66 million during the quarter, compared to the consensus estimate of $0.66 million. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%. View Spero Therapeutics' Earnings History. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Spero Therapeutics. What price target have analysts set for SPRO? 4 equities research analysts have issued 12 month price objectives for Spero Therapeutics' stock. Their forecasts range from $9.00 to $30.00. On average, they anticipate Spero Therapeutics' share price to reach $23.50 in the next year. This suggests a possible upside of 189.8% from the stock's current price. View Analyst Price Targets for Spero Therapeutics. What is the consensus analysts' recommendation for Spero Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics. What are Wall Street analysts saying about Spero Therapeutics stock? Here are some recent quotes from research analysts about Spero Therapeutics stock: 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (1/12/2019) 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts throughout 2018+." (8/9/2018) Has Spero Therapeutics been receiving favorable news coverage? News headlines about SPRO stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spero Therapeutics earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include Crinetics Pharmaceuticals (CRNX), AMAG Pharmaceuticals (AMAG), Assembly Biosciences (ASMB), Arvinas (ARVN), Collegium Pharmaceutical (COLL), NuCana (NCNA), Innate Pharma (IPHYF), Zymeworks (ZYME), Eidos Therapeutics (EIDX), Obseva (OBSV), Flexion Therapeutics (FLXN), Forty Seven (FTSV), Akorn (AKRX), Theratechnologies (THERF) and Prothena (PRTA). Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the folowing people: Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)Mr. Joel D. Sendek, CFO & Treasurer (Age 52)Ms. Cristina Larkin, Chief Operating Officer (Age 49)Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)Ms. Sharon Klahre, Director of Investor Relations When did Spero Therapeutics IPO? (SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $8.11. How big of a company is Spero Therapeutics? Spero Therapeutics has a market capitalization of $141.26 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe. What is Spero Therapeutics' official website? The official website for Spero Therapeutics is http://www.sperotherapeutics.com. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected] MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 112 (Vote Outperform)Underperform Votes: 99 (Vote Underperform)Total Votes: 211MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?